Media room >
News >
+ d'info


OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

TORONTO, Oct. 15, 2021 /CNW/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada approved OPSYNVI® (macitentan 10mg and tadalafil 40mg) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to reduce morbidity in patients of WHO functional class (FC) II or III whose PAH is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.

Read more

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

BURLINGTON, ON, March 4, 2021 /CNW/ – Boehringer Ingelheim (Canada) Ltd. is pleased to announce positive recommendations from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux (INESSS) for OFEV® (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype (also known as PF-ILD) when certain conditions are met.

Read more

Launch of Scleroderma Quebec’s summer funding campaign

June is scleroderma awareness month in Canada and the Unites States. It is a privileged time to inform and raise awareness of the general public on the existence of this little-known and orphan disease and the capital importance of research to find a curative treatment. On this occasion, Scleroderma Quebec launches the “Demystify scleroderma” campaign. Share in large numbers!



OFEV® (nintedanib) now available in Canada for progressive fibrotic interstitial lung diseases (PF-ILD)

BURLINGTON, ON, May 25, 2020 /CNW/ – Boehringer Ingelheim (Canada) Ltd. announced today that OFEV® (nintedanib) is authorized for sale by Health Canada for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD).